ライフサイエンスコーパス: age-related

1 onocytes into Dysf-deficient BLA/J mice with age-related (2 to 10 months) muscle disease and Dysf-int

2 se results demonstrate that there are robust age-related alterations in gene expression in the human

3 Age-related alterations in immunity have been linked to

4 Age-related alterations in the human blood system occur

5 monocyte subsets did not reveal significant age-related alternations; however, agonist stimulated-mo

6 sis factor alpha (TNFalpha) are increased in age-related and chronic conditions such as atheroscleros

7 Multiple age-related and injury-induced characteristics of the ad

8 y levels as continuous variables showed that age-related antibody levels to Circumsporozoite Protein

9 Insight into age-related antibody responses to newly emerging H3N2v v

10 insights into the mechanism controlling the age-related beige-to-white adipocyte transition and iden

11 erated cardiovascular aging, we also studied age-related cardiac remodeling.

12 mice were subjected to the investigation of aging-related cardiac hypertrophy.

13 ent and to contribute to both congenital and age related cataract when mutated, the extended promoter

14 amily, accumulated over a lifetime, leads to age-related cataract, whereas inherited mutations are as

15 symptom onset) and 15 control patients with age-related cataract.

16 of decline of lung function is greater than age-related change in a substantial proportion of patien

17 ome-wide patterns of DNA methylation so that age-related changes are profoundly delayed, while change

18 integrity during adulthood and show that its age-related changes can be rescued by a TIE2 agonistic a

19 ases significantly with age, coinciding with age-related changes in body composition that are common

20 We discovered distinct age-related changes in both model organisms.

21 Age-related changes in crowding may in part explain slow

22 g have identified subsets of genes that show age-related changes in expression.

23 erations in colonic 5-HT signalling underlie age-related changes in faecal output in mice and whether

24 dial temporal lobe (MTL) in episodic memory, age-related changes in MTL structure and function may pa

25 ated tau 181/beta-amyloid 42 levels modulate age-related changes in myelin water fraction.

26 we present here a comprehensive study of the age-related changes in the Arabidopsis thaliana glycated

27 that underlie interindividual variability in age-related changes in the brain.

28 icity in the nucleus accumbens is central to age-related changes in voluntary running.

29 recent developments in the understanding of age-related changes that affect key components of immuni

30 Immunosenescence is a series of age-related changes that affect the immune system and, w

31 Understanding age-related changes to the UPR(ER) will provide new aven

32 of proteostasis is associated with aging and age-related chronic disease.

33 the splicing machinery is linked to several age-related chronic illnesses.

34 This review discusses the age-related clonal expansions in the human HSPC pool, wh

35 uman HSPC pool, which was termed in the past age-related clonal hematopoiesis (ARCH).

36 Next generation sequencing (NGS) discovered age-related clonal hematopoiesis of indeterminate potent

37 derstood and raising the possibility that an age-related clonal process of preleukemic cells could pr

38 evels of social support were associated with age-related cognitive decline and whether these associat

39 Age-related cognitive decline has many contributors, and

40 Associations between social support and age-related cognitive decline vary across different rela

41 B modulation as a potential therapy to treat age-related cognitive decline.

42 to by international differences in rates of age-related cognitive decline.

43 bute to the identification of treatments for age-related cognitive deficits.SIGNIFICANCE STATEMENT Pe

44 pollution exposure has been associated with age-related cognitive impairment, possibly because of en

45 ramidal neurons is believed to contribute to age-related cognitive impairments.

46 E (apoE) is a strong genetic risk factor for aging-related cognitive decline as well as late-onset Al

47 Age-related complications such as neurodegenerative diso

48 Immunosenescence, an age-related decline in immune function, is a major contr

49 Chronic, moderately lowered IIS rescues age-related decline in neurotransmission through the Dro

50 omy-related reduction in GFR, followed by an age-related decline that may be more rapid in related do

51 in the NAc may be partially responsible for age-related declines in voluntary running behaviour.

52 ants performed two cognitive tasks that show age-related decrease (fluid intelligence and object nami

53 only reported example of such a change is an age-related decrease in the recruitment of posterior sen

54 we investigate brain maturation, indexed by age-related decreases in cortical thickness, in adolesce

55 ns during search replicated prior reports of age-related decreases in posterior recruitment and incre

56 that show performance declines with age show age-related decreases in task-positive activation of neu

57 and that caloric restriction prevents these age-related decreases.

58 ie restriction reduces or delays many of the age-related defects that occur in rodent skeletal muscle

59 rategies to improve clonal selection against age related deterioration.

60 al ageing further helps to determine risk of age-related deterioration and death.

61 ived with UTE imaging are good predictors of age-related deterioration of cortical bone structure and

62 tion of late-life exercise training reverses age-related diastolic and microvascular dysfunction.

63 ysfunction contributes to the development of age-related diastolic dysfunction, and (2) initiation of

64 We identify a multivariate profile of age-related differences in intrahippocampal structures a

65 Osteoarthritis is an age-related disease and cellular senescence is predicted

66 ve to humans, potentially protecting against age-related disease caused by haploinsufficiency.

67 development of effective treatments for the age-related disease osteoarthritis and the ability to pr

68 chondrial genome has long been implicated in age-related disease, but no studies have examined its ro

69 the immune system in the development of this age-related disease.

70 has also been implicated as a major cause of age-related disease.

71 gth, a potential marker of susceptibility to age-related disease.

72 emerging as good indicators for diabetes and age related diseases.

73 HRD or Laron syndrome) are protected against age-related diseases including cancer and diabetes.

74 also increase the probability of developing age-related diseases such as Alzheimer's disease, Parkin

75 en in stroke, or more chronic as observed in age-related diseases such as Parkinson's disease.

76 cell communication, and pathogenesis of many age-related diseases.

77 tissues is a major contributor to aging and age-related diseases.

78 and hence alter the propensity for a host of age-related diseases.

79 a new therapeutic approach for obesity- and aging-related diseases associated with mitochondrial dys

80 prevent telomere-associated diseases, namely aging-related diseases, including cancer.

81 and stress responses, and are implicated in aging-related diseases.

82 Cognitive deficits in psychiatric and age-related disorders generally involve dysfunction of t

83 ion extends lifespan and delays the onset of age-related disorders in most species but its impact in

84 ectionally diverse associations with several age-related disorders, including cardiovascular disease,

85 These age-related disparities in HIV continuum of care are owi

86 This may be due to age-related dopamine (DA) decline affecting neural proce

87 d that clustered PDAC into 4 major subtypes: age related, double-strand break repair, mismatch repair

88 revealed that each modality exhibits unique age-related effects and sex differences.

89 h age, GMD increases and shows the strongest age-related effects, while GMM shows a slight decline ov

90 laxation was evident after the occurrence of age-related endothelial dysfunction and diminished diste

91 in the entorhinal cortex, as a substrate of age-related episodic-memory loss.

92 Age-related estrogen deficiency leads to accelerated bon

93 aporean Malay population and to validate the Age-Related Eye Disease Study (AREDS) simplified severit

94 Age-Related Eye Disease Study 2 Ancillary SD OCT study p

95 substantial agreement with the gold standard Age-related Eye Disease Study data set.

96 Using small interfering RNA, well-studied age-related factors (i.e., rapamycin, resveratrol, TNF-a

97 ction may prove to be beneficial in treating age-related functional hematopoietic decline.

98 aged rats, prevented many of the hippocampal age-related gene expression changes.

99 hnology to quantify the effects of aging and age-related genetic and chemical factors in the calcium

100 anner and clearly indicated the existence of age-related glycation hot spots in the plant proteome.

101 phenotype is associated with amelioration of age-related gut pathology and functional decline, dampen

102 ABSTRACT: Age-related hearing loss (ARHL) is associated with chang

103 Recent research has linked age-related hearing loss to impaired performance across

104 r leads to neurodegeneration and exacerbates age-related hearing loss.

105 Many age-related human diseases have inflammatory components

106 Despite huge motivation to treat age-related human memory disorders, interaction between

107 Furthermore, we demonstrate that age-related IFN-I milieu downregulates microglial myocyt

108 entify functional changes that contribute to age-related impairments in cognitive performance.

109 ion, TGF-beta expression, and, most notably, age-related impairments in mitochondrial biogenesis and

110 sion of securin or Mps1 protects against the age-related increase in inter-sister kinetochore distanc

111 isms underlying knowlesi malaria, and of the age-related increase in risk of severe malaria in genera

112 These mice exhibit age-related increases in Abeta production, plaque deposi

113 aloric restriction-like effects and reversed age-related increases in proteinuria, podocyte injury, f

114 -specific trends including multiple distinct age-related inflections that were more pronounced in mal

115 Sestrin2 prevents age-related intolerance to ischemia and reperfusion inju

116 ere defects in ductal branching and abnormal age-related involution compared to littermate controls.

117 entional measures that slows down and delays age-related kidney disease is caloric restriction.

118 ediator of leaf traits, provides evidence of age-related leaf reflectance changes that have important

119 iased hierarchical clustering of patterns of age-related leukocyte dynamics.

120 , which supports patch clamp data showing an age-related loss in ACh efficacy in evoking postsynaptic

121 ured human cells and in flies, and to rescue age-related loss of GJs and of GFS function.

122 dioligand binding studies show a significant age-related loss of heteromeric nAChR receptor number, w

123 related genes Pink1 or Parkin suppresses the age-related loss of tissue homeostasis, despite dramatic

124 by memory CD8(+) T cells, which exhibited an aging-related loss in binding of NF-kappaB and STAT fact

125 etinal vein occlusion (RVO), and neovascular-age related macular degeneration (nvAMD).

126 Age related macular degeneration is the leading cause of

127 ms regulating the normal and diseased state (age related macular degeneration, AMD) in the retina.

128 vision impairment) and a high prevalence of age-related macular degeneration (>14% of blindness) as

129 ong women, with no sex difference related to age-related macular degeneration (0.91 [0.70-1.14]).

130 ractive error (61.3%), cataract (13.2%), and age-related macular degeneration (10.3%).

131 .6 million [18.2 million to 109.6 million]), age-related macular degeneration (8.4 million [0.9 milli

132 Age-related macular degeneration (AMD) affects millions

133 Age-related macular degeneration (AMD) affects the retin

134 bevacizumab for the treatment of neovascular age-related macular degeneration (AMD) among Medicare be

135 23 (60%) had geographic atrophy secondary to age-related macular degeneration (AMD) and 2 eyes (5%) h

136 ix of 15 eyes were diagnosed with coincident age-related macular degeneration (AMD) and 2 with myopic

137 Age-related macular degeneration (AMD) and related macul

138 hy (OCT) images of patients with neovascular age-related macular degeneration (AMD) and to demonstrat

139 o late-stage non-neovascular and neovascular age-related macular degeneration (AMD) and to provide re

140 ence of ethnicity on the association between age-related macular degeneration (AMD) and vision-specif

141 a reported decline in the risk of developing age-related macular degeneration (AMD) continued for peo

142 ctor H (CFH) gene and their association with age-related macular degeneration (AMD) have been describ

143 rmine the 6-year incidence of early and late age-related macular degeneration (AMD) in a Singaporean

144 secutive naive eyes diagnosed with exudative age-related macular degeneration (AMD) in comparison wit

145 ce to a Mediterranean diet and prevalence of age-related macular degeneration (AMD) in countries rang

146 evaluate the incidence of intermediate-stage age-related macular degeneration (AMD) in patients with

147 Age-related macular degeneration (AMD) is a leading caus

148 Age-related macular degeneration (AMD) is a major cause

149 Age-related macular degeneration (AMD) is a progressive

150 Age-related macular degeneration (AMD) is the leading ca

151 Age-related macular degeneration (AMD) is the most commo

152 To evaluate the impact of age-related macular degeneration (AMD) on short out-loud

153 at-and-extend (TREX) regimen for neovascular age-related macular degeneration (AMD) or fellow control

154 type 1 neovascularization (NV) in eyes with age-related macular degeneration (AMD) receiving anti-va

155 RNAs (miRs) in diabetic retinopathy (DR) and age-related macular degeneration (AMD) remains unclear.

156 cted loss-of-function (pLoF) variants within age-related macular degeneration (AMD) risk loci and AMD

157 en genetic predictors of lipid fractions and age-related macular degeneration (AMD) risk.

158 stionnaire (LLQ) in patients with a range of age-related macular degeneration (AMD) severity are asso

159 ographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) that leads to pro

160 visual outcome in patients with neovascular age-related macular degeneration (AMD) treated initially

161 plasma metabolomic profile of patients with age-related macular degeneration (AMD) using mass spectr

162 he retinal pigment epithelium (RPE) cells in age-related macular degeneration (AMD) using polarimetry

163 d be part of standard care for patients with age-related macular degeneration (AMD) who are being con

164 y 2 Ancillary SD OCT study participants with age-related macular degeneration (AMD) with bilateral la

165 RD shows striking phenotypic similarities to age-related macular degeneration (AMD), a common and gen

166 Age-related macular degeneration (AMD), a leading contri

167 Age-related macular degeneration (AMD), a multifactorial

168 Other diseases, such as age-related macular degeneration (AMD), develop late in

169 cross a diverse range of diseases, including age-related macular degeneration (AMD), glaucoma and ref

170 In age-related macular degeneration (AMD), rare variants in

171 ctively recruited patients with intermediate age-related macular degeneration (AMD), without other vi

172 systemic inflammation increases the risk of age-related macular degeneration (AMD).

173 ceptor alterations in eyes with intermediate age-related macular degeneration (AMD).

174 ed high-fat intakes with a high incidence of age-related macular degeneration (AMD).

175 lop drusenoid lesions which are hallmarks of age-related macular degeneration (AMD).

176 s supposed to contribute the pathogenesis of age-related macular degeneration (AMD).

177 al OCT images from images from patients with Age-related Macular Degeneration (AMD).

178 ing inflammatory marker associated with late age-related macular degeneration (AMD).

179 and the intermediate and advanced stages of age-related macular degeneration (AMD).

180 izumab with aflibercept to treat neovascular age-related macular degeneration (AMD).

181 light contribute to the oxidative stress in Age-related macular degeneration (AMD).

182 ophy based on OCT findings in the setting of age-related macular degeneration (AMD).

183 hway, are altered in patients with exudative age-related macular degeneration (AMD).

184 e and inflammatory retinal disorders such as age-related macular degeneration (AMD).

185 d in the retinal pigment epithelium (RPE) of age-related macular degeneration (ARMD) patients and the

186 is associated with neovascularization in wet age-related macular degeneration (ARMD), choriocapillari

187 phic atrophy (nGA) in eyes with intermediate age-related macular degeneration (iAMD).

188 visual outcomes in patients with neovascular age-related macular degeneration (nAMD) during anti-vasc

189 onthly regimens in patients with neovascular age-related macular degeneration (nAMD) from the TReat a

190 Describing the natural course of neovascular age-related macular degeneration (nAMD) is essential in

191 Treatment-naive eyes with neovascular age-related macular degeneration (nAMD) tracked by the F

192 raphic atrophy (GA) in eyes with neovascular age-related macular degeneration (nAMD) treated with ran

193 nts treated with ranibizumab for neovascular age-related macular degeneration (nAMD), diabetic macula

194 mab monotherapy in patients with neovascular age-related macular degeneration (nAMD).

195 phy (OCT) in guiding therapy for neovascular age-related macular degeneration (nvAMD) to the research

196 eat-and-extend (TAE) regimen for neovascular age-related macular degeneration (NVAMD).

197 aps significantly with sets found by GWAS of age-related macular degeneration (P=1.4 x 10(-12)), ulce

198 growth factor inhibitors (anti-VEGF) for wet age-related macular degeneration (wAMD), and to acquire

199 Age-related macular degeneration 4 included neovascular

200 ents aged 50 years or older with neovascular age-related macular degeneration and a baseline best-cor

201 To report patients with age-related macular degeneration and atypical central re

202 other retinal degenerative diseases such as age-related macular degeneration and diabetic retinopath

203 tial therapies for retinal diseases, such as age-related macular degeneration and inherited retinal d

204 se vision loss in many eye diseases, such as age-related macular degeneration and macular telangiecta

205 Age-related macular degeneration automated detection was

206 itreous bevacizumab injections for exudative age-related macular degeneration between January 1, 2009

207 Geographic atrophy is a blinding form of age-related macular degeneration characterized by retina

208 of European ancestry from the International Age-related Macular Degeneration Genomics Consortium.

209 Age-related macular degeneration may be more than a "mac

210 h factor agents for treatment of neovascular age-related macular degeneration or diabetic macular ede

211 When a patient with neovascular age-related macular degeneration or diabetic macular ede

212 (2017) show that iPSC-derived RPE cells from age-related macular degeneration patients express increa

213 million (17.9 million to 124.1 million), by age-related macular degeneration to 8.8 million (0.8 mil

214 w-up among participants in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT

215 ective cohort study within the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT

216 Age-related macular degeneration was attributed as the m

217 We applied our method to an in-depth GWAS of age-related macular degeneration with 33,976 individuals

218 that recombinant I62-CFH (protective against age-related macular degeneration) and V62-CFH functioned

219 ic macular edema, 32 (25.8%) had neovascular age-related macular degeneration, and 32 (25.8%) had oth

220 sregulated in various pathologies, including age-related macular degeneration, arthritis, and cancer.

221 treatment of ophthalmic diseases, including age-related macular degeneration, cataracts, diabetic re

222 e anterior (dry eye syndrome) and posterior (age-related macular degeneration, diabetic retinopathy a

223 Ophthalmic diseases, such as age-related macular degeneration, glaucoma, and diabetic

224 The other, age-related macular degeneration, is the most common for

225 hat critically contributes to vision loss in age-related macular degeneration, is unclear.

226 An exemplary search for patients with age-related macular degeneration, performed cataract sur

227 hy of prematurity, diabetic retinopathy, and age-related macular degeneration, threaten the visual he

228 to managing diseases, including stroke, AD, age-related macular degeneration, traumatic brain injury

229 sFLT01 in patients with advanced neovascular age-related macular degeneration.

230 g proliferative diabetic retinopathy and wet age-related macular degeneration.

231 d improved visual outcomes for patients with age-related macular degeneration.

232 ch as retinitis pigmentosa (RP) and atrophic age-related macular degeneration.

233 rders as proliferative vitreoretinopathy and age-related macular degeneration.

234 the protective effect of FHR-1 deficiency in age-related macular degeneration.

235 s with common eye diseases like glaucoma and age-related macular degeneration.

236 can resolve ambiguity about cone survival in age-related macular degeneration.

237 rding to the International Classification of Age-related Maculopathy and Macular Degeneration.

238 the International Classification System for age-related maculopathy and stratified using the Rotterd

239 ages were graded for AMD using the Wisconsin Age-related Maculopathy Grading System.

240 Presence of AMD as defined by the Clinical Age-Related Maculopathy Staging system based on color fu

241 In this study, we identified an age-related mechanism along the cholinergic nerve-airway

242 s therefore represent one pathway explaining age-related memory decline.

243 ubfield structure and function contribute to age-related memory impairment, complementing findings in

244 in aggregation as an underlying mechanism of age-related memory impairment.SIGNIFICANCE STATEMENT Alt

245 However, the role of AGEs in age-related molecular alterations in plants is still unk

246 the aging brain, and provide a link between aging-related molecular changes and functional decline.

247 and the causal role of muscular strength in age-related morbidities and mortality.

248 ymptoms are associated with vulnerability to age-related morbidity and mortality.

249 ity as an epigenetic clock and prognostic of age-related morbidity and mortality.

250 These mice display age-related motor deficits and degeneration of the nigro

251 to predict the effect of selected miRNAs on age-related muscle wasting.

252 al, and molecular analyses revealed that the age-related myocardial impairment occurs in parallel wit

253 led that T cells significantly contribute to age-related myocardial inflammation and functional decli

254 Age-related neural patterns during search replicated pri

255 vitamin B3 in glaucoma and potentially other age-related neurodegenerations.

256 ophysiology in heritable brain disorders and age-related neurodegenerative and cognitive decline.

257 how microglial senescence may contribute to age-related neurodegenerative diseases.

258 tial therapeutic target in breast cancer and age-related neurodegenerative diseases; however, CYP27A1

259 n's disease, and Multiple System Atrophy are age-related neurodegenerative disorders characterized by

260 Protein aggregation is associated with age-related neurodegenerative disorders, such as Alzheim

261 lead to therapeutic advances that ameliorate age-related neurodegenerative pathologies.

262 of entorhinal cortex (reflecting incidental age-related neurofibrillary tangles) and neuromelanin-co

263 mechanism for therapeutic intervention into aging-related neuronal disorders.

264 We argue that reversals may not represent aging-related neuronal loss.

265 chronic and acute myeloid malignancies; (3) age-related niche changes and their suspected impact on

266 ng the optical axis of human eye lenses with age-related nuclear cataract showed increasing concentra

267 ucose homeostasis and were protected against age-related obesity and insulin resistance.

268 e aging process itself could ameliorate many age-related pathologies.

269 To study the clinical spectra and age-related penetrance of individuals with mutations in

270 ion in epigenetic age predicting a number of age-related phenotypes.

271 n of Pofut1 in skeletal myofibers can induce aging-related phenotypes in cis within skeletal myofiber

272 Age-related physiologic differences in eosinophil molecu

273 Cataglyphis desert ants exhibit an age-related polyethism, with ants performing tasks in th

274 nd a syntactic comprehension task that shows age-related preservation.

275 bacterial mutants also protect the host from age-related progression of tumor growth and amyloid-beta

276 er examination of the presence and effect of age-related quality differences.

277 that adipose tissue macrophages regulate the age-related reduction in adipocyte lipolysis in mice by

278 ty, whereas APOEepsilon4+ individuals showed age-related reduction of modulation in response to incre

279 imately 195 in murine endothelium alleviates age-related reduction of type CD31(hi)Emcn(hi) vessels a

280 ions with age-which we term genosenium-shows age-related, region-related, and disease-related molecul

281 lacuna and age at death may reflect reported age-related responses to microdamage.

282 s to the pathology of metastatic cancers and age-related retinopathies.

283 Consistently, age-related SC loss in the mouse trachea and in muscle c

284 We highlight a common but age-related Sema4a-mediated pathway by which pDCs and mi

285 ory recruitment of prefrontal regions due to age-related sensory-processing deficits in posterior reg

286 gainst 2012-2013 H3N2v viruses was >50%, and age-related seroprevalence was observed.

287 and potentially could serve as a remedy for age-related skin atrophy.

288 hese and other emerging studies suggest that age-related sleep disruption may be one key factor that

289 hort to investigate the relationship between age-related structural differences and visual evoked fie

290 nergic efficacy may also be the result of an age-related subunit switch from high affinity beta2-cont

291 In terms of non-AD pathologies, both primary age-related tauopathy (p < 0.05) and brain arterioloscle

292 in the development of treatments to prevent age related tendinopathy.

293 are well-known markers of aging, and impact age-related tissue stiffening and atherosclerotic change

294 Lsd1 expression is sufficient to rescue the age-related transition of beige adipocytes to white adip

295 Quantitative assessments of age-related trends after aging, including mean diameter,

296 atrial arrhythmias, associated factors, and age-related trends.

297 xt encoding, a process that does not exhibit age-related variation from middle childhood to late adol

298 Age-related variation in reproductive performance is ubi

299 ed on functional studies in Drosophila, this age-related variation of TK is suggestive of a modulator

300 c cerebral hypoperfusion is a major cause of age-related vascular cognitive impairment.